Competing Interests: The authors of this manuscript have the following competing interests: CK reports
non-financial support from Astellas Pharma Inc., grants from Scientific Research from
the Ministry of Education, Culture, Sports, Science and Technology of Japan, during
the conduct of the study. KT reports non-financial support from Astellas Pharma Inc.,
grants from Ministry of Education, Culture, Sports, Science and Technology of Japan,
during the conduct of the study; grants from Astellas Pharma Inc., grants from Novartis
Pharma K.K., grants from Daiichi Sankyo Company Limited., grants and personal fees
from AstraZeneca K.K., grants and personal fees from Nippon Boehringer Ingelheim Co.,
Ltd., grants and personal fees from MSD K.K., grants and personal fees from Takeda
Pharmaceutical Compamy Limited., personal fees from Kissei Pharmaceutical Co., Ltd.,
grants from Sanofi K.K., personal fees from Novo Nordisk Pharma Ltd., grants and personal
fees from Lilly Japan K.K., personal fees from Ono Pharmaceutical Co., Ltd., grants
from Mochida Pharmaceutical Co., LTD., grants from Terumo Co., Ltd., outside the submitted
work. KS reports non-financial support from Astellas Pharma Inc., grants from Scientific
Research from the Ministry of Education, Culture, Sports, Science and Technology of
Japan, during the conduct of the study. YM reports non-financial support from Astellas
Pharma Inc., grants from Ministry of Education, Culture, Sports, Science and Technology
of Japan, during the conduct of the study. SF reports non-financial support from Astellas
Pharma Inc., grants from Scientific Research from the Ministry of Education, Culture,
Sports, Science and Technology of Japan, during the conduct of the study. NS reports
non-financial support from Astellas Pharma Inc., grants from Scientific Research from
the Ministry of Education, Culture, Sports, Science and Technology of Japan, during
the conduct of the study. SY reports non-financial support from Astellas Pharma Inc.,
grants from Ministry of Education, Culture, Sports, Science and Technology of Japan,
during the conduct of the study. KK reports other from Astellas Pharma Inc., during
the conduct of the study; personal fees from Astellas Pharma Inc., personal fees from
Johnson & Johnson K.K., personal fees from Novartis Pharma K.K., personal fees from
Kowa Pharmaceutical Company LTD., personal fees from Kyowa Hakko Kirin Co., Ltd.,
personal fees from Daiichi Sankyo Company Limited., personal fees from AstraZeneca
K.K., personal fees from Taisho Toyama Pharmaceutical Co., Ltd., personal fees from
Nippon Boehringer Ingelheim Co., Ltd., personal fees from MSD K.K., personal fees
from Takeda Pharmaceutical Compamy Limited., personal fees from Kissei Pharmaceutical
Co., Ltd., personal fees from Sanofi K.K., personal fees from Novo Nordisk Pharma
Ltd., personal fees from Lilly Japan K.K., personal fees from Mitsubishi Tanabe Pharma
Corporation, personal fees from Shionogi & Co., Ltd, personal fees from Ono Pharmaceutical
Co., Ltd., outside the submitted work. YO reports non-financial support from Astellas
Pharma Inc., grants from Ministry of Education, Culture, Sports, Science and Technology
of Japan, during the conduct of the study; grants from Astellas Pharma Inc., grants
from Novartis Pharma K.K., grants from AstraZeneca K.K., grants from Nippon Boehringer
Ingelheim Co., Ltd., grants from MSD K.K., grants from Takeda Pharmaceutical Compamy
Limited., grants from Kissei Pharmaceutical Co., Ltd., grants from Sanofi K.K., grants
from Lilly Japan K.K., grants from Ono Pharmaceutical Co., Ltd., grants from Mochida
Pharmaceutical Co., Ltd., grants from TERUMO CORPORATION, grants from JCR Pharmaceuticals
Co., Ltd, grants from ASKA Pharmaceutical Co., Ltd., grants from Eisai Co., Ltd.,
grants from NIPRO Co., Ltd., grants from Nestle Japan Limited, grants from Pfizer
Japan Inc., grants from Shionogi & Co., Ltd., grants from THERAVALUES CORPORATION,
grants from Kyowa Hakko Kirin Co,. Ltd., grants from Kowa Pharmaceutical Co., Ltd.,
grants from Taisho Toyama Pharmaceutical Co., Ltd., grants from TEIJIN PHARMA LIMITED,
grants from Mitsubishi Tanabe Pharma Corporation, outside the submitted work. This
does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.